LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

ACADIA Pharmaceuticals Inc

Closed

Sector Healthcare

14.88

Overview

Share price change

24h

Current

Min

14.62

Max

15.18

Key metrics

By Trading Economics

Income

-29M

17M

Sales

-25M

206M

EPS

0.1

Profit margin

8.044

Employees

597

EBITDA

-16M

21M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+81.47 upside

Dividends

By Dow Jones

Next Earnings

31 lip 2024

Market Stats

By TradingEconomics

Market Cap

-12M

2.5B

Previous open

14.88

Previous close

14.88

News Sentiment

By Acuity

43%

57%

112 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

ACADIA Pharmaceuticals Inc Chart

Related News

18 cze 2024, 19:25 UTC

Acquisitions, Mergers, Takeovers

Nvidia in Deal to Buy Software Startup Shoreline.io, Bloomberg Reports

18 cze 2024, 15:42 UTC

Acquisitions, Mergers, Takeovers

Circle K, Global Partners Sell Dozens of U.S. Stores -- OPIS

18 cze 2024, 21:36 UTC

Market Talk

Fitch Affirms Canadian Bank Ratings, Citing Pending BOC Rate Cuts -- Market Talk

18 cze 2024, 20:59 UTC

Top News

Exxon Lawsuit Against Activist Shareholders Thrown Out -- WSJ

18 cze 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18 cze 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 cze 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 cze 2024, 20:22 UTC

Acquisitions, Mergers, Takeovers

Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover -- IBD

18 cze 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 cze 2024, 19:59 UTC

Market Talk

Canada Finance Officials Aware of 'Rebalancing' in Labor Market -- Market Talk

18 cze 2024, 19:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 cze 2024, 19:43 UTC

Market Talk

Gold Stays Elevated as Central Banks Continue To Buy -- Market Talk

18 cze 2024, 19:17 UTC

Earnings

Investors Shrugged Off Zyn's Latest Trouble. Nicotine Pouches Still Aren't in the Clear. -- Barrons.com

18 cze 2024, 19:07 UTC

Market Talk

Oil Futures Advance as Traders Bet on Seasonal Demand -- Market Talk

18 cze 2024, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

18 cze 2024, 18:00 UTC

Top News

Amazon Fined by California for Failure to Disclose Worker Quotas -- WSJ

18 cze 2024, 17:17 UTC

Market Talk

Brazil's Central Bank Expected To Pause Easing -- Market Talk

18 cze 2024, 17:12 UTC

Market Talk

U.S. Home Prices Rise At Slowest Rate in Nearly 18 Months -- Market Talk

18 cze 2024, 17:00 UTC

Earnings

Kroger Earnings Due As Grocery Archrivals Walmart, Costco Snatch All-Time Highs -- IBD

18 cze 2024, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 cze 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 cze 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 cze 2024, 15:59 UTC

Acquisitions, Mergers, Takeovers

Citi Stock Gains as Bank Showcases an Overlooked Business -- Barrons.com

18 cze 2024, 15:37 UTC

Market Talk

Oil Gains on Expectations of Tighter Market Over Summer -- Market Talk

18 cze 2024, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 cze 2024, 15:35 UTC

Market Talk

German Economic Sentiment Has Plateaued, But Recovery Still on Track -- Market Talk

18 cze 2024, 15:32 UTC

Market Talk

Some Steam Expected to Come Out of Gold Price as Rates Fall -- Market Talk

18 cze 2024, 15:28 UTC

Market Talk

German Economic Sentiment Shrugs off Political Uncertainty -- Market Talk

18 cze 2024, 15:00 UTC

Market Talk

Kering Will Continue to Face Challenges -- Market Talk

18 cze 2024, 14:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Proxy ISS Supports BBVA's Bid for Sabadell -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

81.47% upside

12 Months Forecast

Average 26.93 USD  81.47%

High 39 USD

Low 17 USD

Based on 14 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

14.81 / 15.28Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

112 / 370 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).